Molecular Pathology of Cancer Group

2023 Activity indicators

5 national public competitive projects: ISCIII, FIBioHRC
1 private competitive project led: AECC
2 private projects led
117 clinical led trials
1 competitive HR contract
41 publications
IF: 354.21
Q1 publications: 18 (44%)
D1 publications : 7 (17%)
1 consensus document and 1 recommendations document
Evaluators of national public agency projects: 1 PI
Members of national and international editorial boards: 1 PI
4 visitors hosted and 11 months stay:
- Universidad de Alcalá
- CEU Universidad San Pablo
- Universidad Politécnica de Madrid
- University Chieti-Pescara (Italia)

Piloting of the CAM cervical cancer population screening programme (CERVICAM).
CAM reference centre for the determination of biomarkers by NGS in solid tumours.
Participation in three ISCIII Personalised Medicine projects.
Participation in collaborative cancer research networks within the framework of CIBERONC.
Incorporation of new researchers from the Medical Oncology Service of the Ramón y Cajal University Hospital, reinforcing the translational capacity of the group and opening up new lines of research.

	Article	Accum. FI	Mean FI	Articles Q1 or Q2	% in Q1 or Q2	Articles D1	% on D1
2019	13	38.02	2.92	7	54	1	8
2020	17	69.25	4.07	12	71	5	29
2021	17	102.25	6.01	13	76	2	12
2022	25	149.83	5.99	18	72	6	24
2023	41	354.21	10.42	27	66	7	17
	113	713.56	5.89	77	68	21	19